Breast cancer exhibits significant heterogeneity, with approximately 15–20% of patients with breast cancer being diagnosed with the triple-negative subtype (TNBC), which is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (Her-2) gene expression [2]. This evidence concerns the gene ESR1 and breast cancer.